PSNL News and Press, Personalis Inc. From 05/04/22

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Reported quarterly revenue of $15.2 million in the first quarter of 2022 ...

Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion’s personalized cancer immunotherapy EVX-01. The study will combin...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position of Vice President of Diagnostic Sales. This appointment supports the company’s objective to accelerate expansion in...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. P...

Tool detects increasingly important biomarker for immunotherapy Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of its study titled, " A machine learning algorithm with subclonal sensitivity reveals wid...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced the issuance of a key US Patent related to its industry-leading minimal residual disease (MRD) and recurrence platform, NeXT Personal . The patent, US Patent No. 11,299,783, entitled “Met...

Profiling feasibility study uses a combined transcriptome and exome approach to confirm and augment upon previous molecular subtyping method in colorectal cancer Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced its co-authorshi...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 21 st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 2:15 p.m. Eastern Time. About Personalis Personalis,...

Personalis’ oncology diagnostics business expected to build on foundation of advanced technology already the driver of rapidly growing revenue from pharmaceutical companies Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today an...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced it is presenting new data in scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2022 , which will be held in-person and online, April 8-13, 2022. ...